John Losee, MD
Urology · Washington, DCNPI 1932138906
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,365 of the $8,764 with a category attached, or 72.6%. It is spread thinly across 40 manufacturers, the largest accounting for just 21.4%. 2025 is the largest year on record at $5,080, more than ten times the $412 reported in 2019.
Across 257 payments — averaging $34.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- Boston Scientific$1K
- Astellas Pharma US Inc$1K
- Procept Biorobotics Corporation$995
- Axonics, Inc.$475
- Sumitomo Pharma America, Inc.$333
- plus $3K from 34 others
What the payments were for
- Travel & lodging$2,07624%
- Food & beverage$6,36573%
- Education$3234%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 6 | $1,872 |
| Boston Scientific | 13 | $1,216 |
| Astellas Pharma US Inc | 52 | $1,009 |
| Procept Biorobotics Corporation | 13 | $995 |
| Axonics, Inc. | 16 | $475 |
| Sumitomo Pharma America, Inc. | 16 | $333 |
| Pfizer | 15 | $264 |
| Urogen Pharma, Inc. | 9 | $242 |
| Urovant Sciences Inc | 12 | $229 |
| Endo Pharmaceuticals Inc. | 12 | $212 |
| Johnson & Johnson(2 entities) | 8 | $186 |
| Antares Pharma, Inc. | 7 | $159 |
| AbbVie(2 entities) | 9 | $156 |
| Merck | 8 | $144 |
| Renovia Inc | 3 | $124 |
| Endo USA, Inc. | 5 | $111 |
| Medtronic | 3 | $105 |
| Corcept Therapeutics | 4 | $96 |
| Myriad Genetic Laboratories, Inc. | 5 | $95 |
| Myovant Sciences Inc. | 6 | $93 |
| Profound Medical Corp. | 2 | $71 |
| Bayer | 4 | $68 |
| Amarin Pharma, Inc. | 3 | $53 |
| Tolmar, Inc. | 2 | $53 |
| Tolmar Pharmaceuticals, Inc. | 2 | $41 |
| Laborie Medical Technologies Corp. | 4 | $39 |
| Olympus America Inc. | 2 | $36 |
| Coloplast | 2 | $34 |
| Calyxo, Inc. | 1 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| BD | 1 | $30 |
| Boehringer Ingelheim | 1 | $20 |
| 180 Medical, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Amgen | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $12 |
| Metuchen Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,803
- Barrigel$1,412
- Solyx SIS System$923
- AquaBeam Robotic System$490
How this compares
$8,764 in reported general payments places this provider in the 75th percentile of 47 urology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 93 | $87,651 |
| Tamsulosin Hcl | 663 | $9,823 |
| Estradiol | 86 | $7,055 |
| Finasteride | 309 | $4,269 |
| NitrofurantoinNitrofurantoin Macrocrystal | 131 | $3,925 |
| Oxybutynin Chloride ErOxybutynin Chloride | 110 | $3,207 |
| Methenamine Hippurate | 41 | $2,953 |
| Testosterone | 13 | $2,615 |
| CefuroximeCefuroxime Axetil | 116 | $1,709 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 47 | $1,164 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $828 |
| Dutasteride | 21 | $760 |
| Trimethoprim | 14 | $699 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 18 | $614 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 77 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,009 | $87,65193 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 47 urology providers in District of Columbia.
Other urology in Washington
- Armine SmithWashington$58K
- Nathan ShawWashington$54K
- Lambros StamatakisWashington$39K
- Patrick MufarrijWashington$31K
- Ryan HankinsWashington$29K
- Adam MetwalliWashington$27K
- Michael WhalenWashington$17K
- Pamela ColemanWashington$14K
- Leslie DeaneWashington$13K
- Jason EngelWashington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.